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AbstrACt
Objectives Primary: describe uptake of new implant 
components (femoral stem or acetabular cup/shell) 
for total hip replacements (THRs) in the National Joint 
Registry for England and Wales (NJR). Secondary: 
compare the characteristics of: (a) surgeons and (b) 
patients who used/received new rather than established 
components.
Design Cohort of 618 393 primary THRs performed 
for osteoarthritis (±other indications) by 4979 surgeons 
between 2008 and 2017 in England and Wales from the 
NJR. We described the uptake of new (irst recorded use 
>2008, used within 5 years) stems/cups, and variation 
in uptake by surgeons (primary objectives). We explored 
surgeon- level and patient- level factors associated with 
use/receipt of new components with logistic regression 
models (secondary objectives).
Outcomes Primary outcomes: total number of new 
cups/stems, proportion of operations using new versus 
established components. Secondary outcomes: odds of: (a) 
a surgeon using a new cup/stem in a calendar- year, (b) a 
patient receiving a new rather than established cup/stem.
results Sixty- eight new cups and 72 new stems were 
used in 47 606 primary THRs (7.7%) by 2005 surgeons 
(40.3%) 2008–2017. Surgeons used a median of one 
new stem and cup (25%–75%=1–2 both, max=10 
cups, max=8 stems). Surgeons performed a median 
total of 22 THRs (25%–75%=5–124, range=1–3938) 
in the period 2008–2017. Surgeons used new stems in 
a median of 5.0% (25%–75%=1.3%–16.1%) and new 
cups in a median of 9.4% (25%–75%=2.8%–26.7%) of 
their THRs. Patients aged <55 years old versus those 
55–80 had higher odds of receiving a new rather than 
established stem (OR=1.83, 95% CI=1.73–1.93) and 
cup (OR=1.31, 95% CI=1.25–1.37). Women had lower 
odds of receiving a new stem (OR=0.87, 95% CI=0.84–
0.90), higher odds of receiving a new cup (OR=1.06, 
95% CI=1.03–1.09).
Conclusions Large numbers of new THR components 
have been introduced in the NJR since 2008. 40% of 
surgeons have tried new components, with wide variation 
in how many types and frequency they have been used.
bACkgrOunD
Total hip replacements (THRs) are mainly 
performed to treat pain and functional 
limitation due to osteoarthritis (OA).1 It is 
a highly successful surgical procedure with 
typical 10- year revision rates<5%,2 the current 
National Institute for Health and Care Excel-
lence benchmark.3 However, younger patients 
are more likely to require revision surgery; 
the lifetime revision risk for men having a 
THR in their 50 s is ~35% compared with 
5% in their 70s.4 Such patients may benefit 
the most from developments in THR that 
lead to reduced revision rates or improved 
outcomes. However, they may also be affected 
strengths and limitations of this study
 Ź This study provides a nationally representative de-
scription of the uptake of new implant components 
for total hip replacements in England and Wales.
 Ź This is the irst study to describe the variation in up-
take of new components by surgeons, and surgeon 
characteristics which may be associated with the 
use of new components.
 Ź Although implant component brand names were 
checked by the authors, some components may have 
been reclassiied or we may still have misclassiied 
some components as either new or established, but 
the introduction of unique device identiiers should 
remove this problem in future.
 Ź The surgeon assigned as lead operating surgeon in 
the National Joint Registry for England and Wales 
may not be correct, although consistency between 
our sensitivity and primary analyses indicate that 
this is unlikely to have substantially affected our 
indings.
 Ź Hospital- level or regional variation in suppliers may 
be important factors affecting implant uptake, but 
these were beyond the scope of this study.
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for the longest time if these developments lead to poorer 
outcomes.
Some new implant designs intended to benefit these 
more active and/or younger patients have been high- 
profile failures, for example metal- on- metal THRs5 
including the Articular Surface Replacement (ASR) 
prostheses in particular.6 Many new implants, including 
the ASR,7 were introduced with minimal supporting 
evidence of their effectiveness8 and may offer at best no 
improvement over pre- existing components.9 An influ-
ential agenda for surgery research (IDEAL) was devel-
oped, providing a framework for future investigations 
into surgical innovations, which recommended the 
phased introduction of new medical devices.10 The rapid 
uptake of ASR hip replacements before the publication of 
supporting evidence bypassed IDEAL Stages 2a (‘Devel-
opment’) and 2b (‘Early dispersion and exploration’). 
Instead, long- term monitoring was relied on to monitor 
outcomes (Stage 4).7 It is not clear whether the uptake of 
newer implants has also been rapid.
There is wide variation between and within regions in 
the use of common surgical procedures, which are only 
explained to a small degree by differing patient demands 
and diagnostic practices.11 The large number of different 
components used in primary THRs (127 femoral stems 
and 105 acetabular cups recorded in the National Joint 
Registry for England, Wales, Northern Ireland and the 
Isle of Man (NJR) in 2016)12 may be an important source 
of variation. Many registries describe the volume of 
different implant components used annually but not the 
variation in uptake of new implants between surgeons or 
which patients receive them. More research is needed to 
understand and reduce avoidable variation in outcomes 
created by differences in surgical activity.
We aimed to:
1. Describe the uptake of new implants for THRs in the 
NJR.
2. Describe how this uptake varies by surgeons.
3. Compare surgeons who use new compared with estab-
lished components.
4. Compare patients who receive new compared with es-
tablished components.
MethODs
Data source
The NJR was established in 2003.2 Data entry for Northern 
Ireland and the Isle of Man did not commence until 2013 
and 2015, respectively; therefore, they are excluded from 
this analysis. Key markers of NJR data quality were high 
and stable from 2008 onwards.13
study sample
We included the cohort of patients who received a primary 
THR for OA (±other indications) between 1 January 
2008 and 26 February 2017. We used NJR data from 2003 
onwards to calculate the date each implant component 
was first used and the total number of implantations. 
We excluded people who had not given consent for 
recording of personal details, where the brand of their 
acetabular or femoral components was uncertain, and 
those who received a resurfacing rather than stemmed 
THR. Resurfacing THRs were excluded since patients 
who receive these are a very different demographic from 
those receiving stemmed THRs (significantly younger 
and more likely to be male), and the annual volume is 
very low (~550 in 2017) and decreasing.14
Patient involvement
This study was designed and undertaken without patient 
involvement.
Deinition of new and established implant components
We identified the implant component brand from compo-
nent labels recorded in the NJR. We used the earliest 
recorded use by any surgeon in the NJR of each femoral 
(stem) or acetabular (cup or shell) component to define 
an implant component’s start date. We classified implant 
components with a start date between the beginning of 
NJR data collection (2003) and the end of 2007 as ‘estab-
lished’. This allowed implant components which were in 
use before the NJR started but which may have only been 
used occasionally to be recorded in the NJR and classified 
appropriately as ‘established’. NJR data quality was also 
high and stable from 2008 onwards. Implant components 
with a start date on or after 1 January 2008 and which 
were used within 5 years of this start date were classified as 
‘new’. Those used later than 5 years after their start date 
were classified as ‘established’.
surgeon uptake of new implant components
All surgeons with operations recorded in the NJR are 
assigned an anonymised identifier, and their role in 
the operation (‘consultant in charge’ or ‘operating’) 
is recorded. We summarised each operating surgeon’s 
activity across each calendar- year in which they performed 
≥1 THR. We considered five potential surgeon- level 
factors which may be associated with use of a new compo-
nent in a calendar- year: total volume of THRs performed 
in that year, proportion of those THRs performed 
on patients<55 years old (<10% and≥10%), source of 
funding for THRs (‘100% National Health Service (NHS) 
funded’ or ‘some or all privately funded’), proportion of 
THRs performed on patients with an American Society of 
Anaesthesiologists (ASA) grade III–V (<25% and≥25%), 
and the range of different stem- cup combinations used in 
that calendar- year (‘≤3’, ‘4–6’, ‘7–10’ and ‘>10’). Surgeons 
who performed ≥10% of their THRs on patients aged <55 
years old and those who performed ≥25% of their THRs 
on patients with ASA III–V were in approximately the 
upper quartile of these distributions.
Patients receiving new implant components
We used date of surgery to order patients within implant 
components and within surgeons. We categorised patients 
according to whether the component they received 
was new or established. We considered five potential 
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patient- level factors which may be associated with their 
receipt of new components: age at the time of THR (<55, 
55–80 and 80+ years), gender, body mass index (BMI), 
ASA grade and NHS or private funding. We selected these 
categories for age to reflect patients who were having a 
primary THR at a relatively young or relatively old age, 
the median age at the time of primary THR was 69 years 
(25%–75% 61–76 years).14
statistical analyses
We described the use of unique stems and cups in primary 
THRs performed since 1 January 2008, the cumulative use 
of new components in patients and the count of surgeons 
who used new components. We also described the total 
number of all and new cups, stems and combinations.
Surgeon-level factors
In analyses of surgeon- level and patient- level factors asso-
ciated with use of or receipt of new implants we included 
only those people with complete exposure and outcome 
data for the surgeon- level and patient- level analysis 
models (ie, complete case analysis). We assumed that data 
were missing at random but did not use multiple imputa-
tion to account for these missing data since there were no 
variables in the NJR dataset which were not already in our 
regression models and which may have carried informa-
tion about the missing data (particularly BMI).
Our outcome was whether a surgeon used a new 
component at least once for a THR in a calendar- year 
(stems and cups analysed separately), unit of analysis was 
surgeon calendar- years and exposure variables were those 
surgeon- level factors defined previously. We used multi-
variable logistic regression models, accounting for the 
clustering of calendar- years within surgeons.
Patient-level factors
Our outcome was whether a patient received a new rather 
than established component (stems and cups analysed 
separately), unit of analysis was patients and exposure 
variables were those patient- level factors defined previ-
ously. Patient- level factors were included in multivariable 
mixed- effects logistic regression models, with patients 
nested within surgeons.
Sensitivity analyses
We conducted three sensitivity analyses. To determine 
whether the lack of variability in patients operated on 
by low volume surgeons affected our results we repeated 
our surgeon- level analysis excluding calendar- years for 
surgeons in which they performed <10 THRs. We also 
considered that the choice of component was made by the 
consultant in- charge rather than the operating surgeon 
(the consultant in- charge was not the operating surgeon 
for ~16% of THRs). We repeated our surgeon- level anal-
ysis by consultant in- charge and repeated our patient- 
level analysis with patients clustered within consultant 
in- charge.
In order to determine the extent to which patients with 
complete data for all exposures and outcome variables 
differed from those missing some exposure data (mainly 
BMI) we compared these groups using chi- square tests. 
We also repeated our patient- level analyses for those 
patients with complete data for all exposure variables 
(including BMI) but excluding BMI from the model, and 
for those with complete data for all exposure variable 
(excluding BMI).
All analyses were performed using Stata V.15 
(StataCorp).
results
Overall use of implant components
Between 1 January 2008 and 26 February 2017, 618 393 
primary THRs were performed for OA in England and 
Wales and recorded in the NJR, corresponding to 23 887 
calendar- years in which surgeons performed ≥1 THR. The 
mean age of the patients was 68.5 years (SD=11.1 years), 
60.7% were female, their ASA grades were I: 14.2%, II: 
69.9%, III: 15.5% and IV/V: 0.5%. Twenty- three per 
cent had a normal/underweight BMI, 39.6% were over-
weight and 37.6% obese. THRs were performed by 4979 
surgeons using 189 different stems, 187 cups and 2026 
stem- cup combinations. Surgeons used a median of three 
different stems (25%–75%=2–5, max=21), four cups 
(25%–75%=2–7, max=27) and five combinations (25%–
75%=2–9, max=60). They performed a median total of 22 
THRs between 2008 and 2017 (25%–75%=5–124, range 
1–3938), although this includes surgeons who started 
part way through this period, retired or changed their 
practice. Excluding calendar- years in which a surgeon 
performed no THRs, the median number of THRs 
surgeons performed per year was 11 (25%–75%=3–35, 
range 1–584) and in 47% of surgeon calendar- years (11 
164 of 23,887) surgeons performed <10 THRs.
use of new implant components
During this period 68 new cups (47 uncemented, online 
supplementary table S1) and 72 new stems (51 unce-
mented, online supplementary table S2) were first used. 
The rate of introduction of new cups and stems remained 
stable (~16 new components/year, online supplementary 
figure S1). Eight per cent (n=47 606) of THRs performed 
used a new stem, cup, or combination. Forty per cent 
(n=2005) of surgeons who performed a THR in this 
period used at least one new implant component.
New cups were used in 5.8% (n=35 885) THRs 
performed by 34.1% (n=1699) surgeons (online supple-
mentary table S1), new stems in 2.9% (n=18 159) THRs 
by 22.3% (n=1111) surgeons (online supplementary 
table S2) and new combinations in 1.0% (n=6438) 
THRs by 8.7% (n=433) surgeons. Most new cups (n=19 
775, 55.1%) and almost all new stems (n=15 361, 
84.6%) were uncemented. The median number of new 
stems, cups and combinations used by surgeons was 
one (25%–75%=1–2, cups max=10, stems max=8 and 
combinations max=9; online supplementary table S3 - 
S5). The median THRs performed using new stems was 
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Figure 1 Cumulative total use of the top ive new stems and cups/shells by days since they were introduced.
three (25%–75%=1–11, max=637) and new cups was 
three (25%–75%=1–14, max=867). The median propor-
tion of a surgeon’s THRs performed using new stems 
was 3.4% (25%–75%=1.0%–10.6%), new cups 6.3% 
(25%–75%=2.0%–18.8%) and new combinations 2.4% 
(25%–75%=0.7%–9.1%).
The five most frequently implanted new stems were 
used in 9049 THRs (49.8% of THRs using a new stem, 
online supplementary table S2). The five most frequently 
implanted new cups were used in 26 962 THRs (75.1% 
of THRs using a new cup, online supplementary table 
S1). Uptake of the two most popular new cups was rapid 
(5000 uses of Exeter X3 Rimfit 1016 days, 5000 uses of 
Trinity 1651 days after first use, figure 1) but was slower 
for new stems (2000 uses of Polarstem Cementless 1670 
days, figure 1). Conversely, a third of the new stems and 
cups (n=26/72 new stems, n=25/69 new cups) have been 
used in ≤10 THRs, and most of these have been used in 
≤5 THRs (n=22 stems, n=20 cups).
surgeon-level and patient-level factors associated with new 
implant components
Our complete case analysis included 431 955 out of 
a possible 618 393 THRs (69.8%) and 20 410 out of a 
possible 23 887 surgeon calendar- years (85.4%, online 
supplementary figure S2). We were missing patient- level 
data for BMI (n=1 86 308, 30.1%) and source of funding 
(n=1514, 0.2%). The characteristics of the subset of 
patients with complete data are shown in online supple-
mentary table S6. There were minor differences between 
people with complete data and those with incomplete data 
(online supplementary table S6). Compared with people 
with incomplete data, a smaller proportion of people with 
complete data were aged ≥80 years old (14.8% vs 16.4%), 
female (60.3% vs 61.6%) and had their operation funded 
through the NHS (86.9% vs 89.4%).
Characteristics of surgeons using new implant components
Multivariable associations between surgeon- level factors 
and their use of new components in a calendar- year were 
consistent between stems and cups (table 1, unadjusted 
online supplementary table S7). Surgeons who treated 
more younger patients had 47% higher odds of using a 
new stem (OR=1.47, 95% CI 1.30 to 1.66, p<0.001) and 
39% higher odds of using a new cup (OR=1.39, 95% 
CI 1.25 to 1.53, p<0.001) in a calendar- year. Those who 
performed more THRs/year had 6% higher odds of 
using new cups (OR=1.06, 95% CI 1.04 to 1.08, p<0.001) 
and 2% higher odds of using new stems (OR=1.02, 95% 
CI 1.00 to 1.05, p=0.206), although the CI crossed the 
null. Private funding was associated with 23% increased 
odds of using new stems (OR=1.23, 95% CI 1.05 to 1.43, 
p=0.010) and weakly associated with 9% increased odds of 
using new cups (OR=1.09, 95% CI 0.96 to 1.23, p=0.187) 
with confidence intervals crossing the null value. Use 
of more stem- cup combinations was strongly associated 
with increased use of new components (ORs for ‘>10’ 
vs ‘≤3’ combinations: 27.4 and 13.3 for stems and cups, 
respectively; p values<0.001). Proportion of patients with 
ASA grades III–IV was weakly associated with 12% higher 
odds of using new cups (OR=1.12, 95% CI 1.01 to 1.25, 
p=0.034) but not with using new stems (OR=1.01, 95% CI 
0.89 to 1.16, p=0.843).
Characteristics of patients receiving new implant components
A higher proportion of recipients of new compared with 
established implant components were aged <55 years old 
(10.5% established vs 21.3% new stems; 10.5% established 
vs 14.8% new cups; table 2), although the main recipi-
ents of all components were aged 55–80 years. Fifteen per 
cent of recipients of established stems (15.0%) were ≥80 
years old compared with 8.3% of recipients of new stems, 
but there was little difference in the proportion of older 
recipients of established (14.9%) and new (13.3%) cups. 
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Table 1 Results from multivariable logistic regression models showing the association between surgeon- level factors and use of new stems and cups
Exposure
Stems Cups
Established
(n=18 404)*
New
(n=2006)* OR† (95% CI) P value†
Established
(n=17 167)*
New
(n=3243)* OR† (95% CI) P value†
Proportion of THRs performed 
on patients <55 years old
                    
  <10% (ref) 13 088
(71.1%)
940
(46.9%)
1 – – 12 346
(71.9%)
1682
(51.9%)
1 – –
  ≥10% 5316
(28.9%)
1066
(53.1%)
1.47 1.30 to 1.66 <0.001 4821
(28.1%)
1561
(48.1%)
1.39 1.25 to 1.53 <0.001
  Number of THRs performed in 
calendar year‡
  (per 10 additional cases)
8
(2, 24)
32
(12, 61)
1.02 0.99 to 1.04 0.206 7
(2, 22)
28
(10, 56)
1.06 1.04 to 1.08 <0.001
Proportion of THRs funded 
privately
                    
  100% NHS funded (ref) 12 922
(70.2%)
966
(48.2%)
1 – – 12 159
(70.8%)
1729
(53.3%)
1 – –
  Some or all funded privately 5482
(29.8%)
1040
(51.8%)
1.23 1.05 to 1.43 0.010 5008
(29.2%)
1514
(46.7%)
1.09 0.96 to 1.23 0.187
Number of stem–cup 
combinations used in calendar 
year
                    
  ≤3 (ref) 14 259
(77.5%)
589
(29.4%)
1 – – 13 599
(79.2%)
1249
(38.5%)
1 – –
  4–6 3394
(18.4%)
822
(41.0%)
4.91 4.25 to 5.67 <0.001 2937
(17.1%)
1279
(39.4%)
3.77 3.36 to 4.23 <0.001
  7–10 675
(3.7%)
468
(23.3%)
12.5 10.1 to 15.4 <0.001 568
(3.3%)
575
(17.7%)
7.21 6.01 to 8.67 <0.001
  >10 76
(0.4%)
127
(6.3%)
27.4 17.9 to 41.7 <0.001 63
(0.4%)
140
(4.3%)
13.3 9.20 to 19.2 <0.001
Proportion of THRs performed 
on patients with ASA grade III–V
                    
  <25% (ref) 13 244
(72.0%)
1554
(77.5%)
1 – – 12 362
(72.0%)
2436
(75.1%)
1 – –
  ≥25% 5160
(28.0%)
452
(22.5%)
1.01 0.89 to 1.16 0.843 4805
(28.0%)
807
(24.9%)
1.12 1.01 to 1.25 0.034
*Proportions displayed are based on surgeon- calendar years.
†ORs, 95% CI and p values are from logistic regression models adjusted for all exposure variables.
‡Median (lower to upper quartile).
ASA, American Society of Anaesthesiologists; NHS, National Health Service; THR, total hip replacement.
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Table 2 Results from multivariable mixed- effects regression models (patients nested within surgeons) of age, gender, categorised BMI, ASA grade and source of funding 
on stem age and cup age, with category proportions
Stems Cups
Established
(n=4 18 831)
New
(n=13 124) OR* (95% CI) P value
Established
(n=4 06 072)
New
(n=25 883) OR* (95% CI) P value
Age
  <55 years old 43 780
(10.5%)
2793
(21.3%)
1.83 1.73 to 1.93 <0.001 42 752
(10.5%)
3821
(14.8%)
1.31 1.25 to 1.37 <0.001
  55–80 (ref) 312 205
(74.5%)
9246
(70.5%)
1 – – 302 823
(74.6%)
18 628
(72.0%)
1 – –
  ≥80 years old 62 846
(15.0%)
1085
(8.3%)
0.60 0.56 to 0.64 <0.001 60 497
(14.9%)
3434
(13.3%)
0.91 0.87 to 0.95 <0.001
Gender
  Male (ref) 165 607
(39.5%)
5768
(44.0%)
1 – – 161 248
(39.7%)
10 127
(39.1%)
1 – –
  Female 253 224
(60.5%)
7356
(56.0%)
0.87 0.84 to 0.90 <0.001 244 824
(60.3%)
15 756
(60.9%)
1.06 1.03 to 1.09 <0.001
BMI
  Underweight and normal 
(ref.)
95 306
(22.8%)
2911
(22.2%)
1 – – 91 863
(22.6%)
6354
(24.5%)
1 – –
  Overweight 165 849
(39.6%)
5138
(39.1%)
1.02 0.97 to 1.08 0.373 160 834
(39.6%)
10 153
(39.2%)
0.95 0.91 to 0.99 0.007
  Class I obese 105 670
(25.2%)
3391
(25.8%)
1.06 1.00 to 1.12 0.067 102 781
(25.3%)
6280
(24.3%)
0.93 0.90 to 0.97 0.001
  Class II obese 38 995
(9.3%)
1276
(9.7%)
1.10 1.02 to 1.19 0.011 37 977
(9.4%)
2294
(8.9%)
0.94 0.89 to 1.00 0.042
  Class III obese 13 011
(3.1%)
408
(3.1%)
0.99 0.87 to 1.11 0.808 12 617
(3.1%)
802
(3.1%)
0.94 0.86 to 1.02 0.135
ASA grade
  I (ref) 60 022
(14.3%)
2661
(20.3%)
1 – – 58 265
(14.3%)
4418
(17.1%)
1 – –
  II 293 142
(70.0%)
8940
(68.1%)
0.81 0.77 to 0.86 <0.001 284 437
(70.0%)
17 645
(68.2%)
0.98 0.95 to 1.03 0.461
  III 63 904
(15.3%)
1482
(11.3%)
0.66 0.61 to 0.72 <0.001 61 681
(15.2%)
3705
(14.3%)
1.00 0.94 to 1.05 0.935
  IV+V 1763
(0.4%)
41
(0.3%)
0.64 0.46 to 0.90 0.010 1689
(0.4%)
115
(0.4%)
1.02 0.82 to 1.26 0.881
Source of funding
Continued
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Across all components and component age, women were 
the main recipients of THRs. There was no difference in 
BMI between recipients of established and new stems or 
cups. A higher proportion of recipients of new compo-
nents had ASA grade I (20.3% new vs 14.3% established 
stems; 17.1% new vs 14.3% established cups). A higher 
proportion of people with privately funded THRs had 
new components (stems: 19.6% new vs 12.9% established; 
cups: 19.5% new vs 12.7% established).
Multivariable mixed effects logistic regression models 
(table 2, unadjusted online supplementary table S8) 
found that patients<55 years old, compared with those 
55–80, had 83% and 31% higher odds of receiving a 
new rather than established stem (OR=1.83, 95% CI 
1.73 to 1.93, p<0.001) and cup (OR=1.31, 95% CI 1.25 
to 1.37, p<0.001). Women had 13% lower odds than 
men of receiving a new stem (OR=0.87, 95% CI 0.84 to 
0.90, p<0.001), but 6% higher odds of receiving a new 
cup (OR=1.06, 95% CI 1.03 to 1.09, p<0.001). There was 
weak evidence that people with higher BMI had 10% 
higher odds of receiving a new stem (OR for under-
weight/normal vs class II obese=1.10, 95% CI 1.02 to 1.19, 
p=0.011) and weak evidence for the converse association 
between BMI and receiving a new cup (eg, OR for under-
weight/normal vs class II obese=0.94, 95% CI 0.89 to 1.00, 
p=0.042). Higher ASA grade was associated with 36% 
lower odds of receiving new stems (OR for ASA grades 
‘IV+V’ vs ‘I’=0.64, 95% CI 0.46 to 0.90, p=0.010), but 
was not associated with receiving new cups (OR for ASA 
grades ‘IV+V’ vs ‘I’=1.02, 95% CI 0.82 to 1.26, p=0.881). 
Patients with private versus NHS funding had 9% higher 
odds of receiving new cups (OR=1.09, 95% CI 1.04 to 1.14, 
p<0.001), but there was no association between source of 
funding and receiving new stems (OR=1.02, 95% CI 0.95 
to 1.08, p=0.642).
sensitivity analyses
Results of our first sensitivity analyses (excluding calendar- 
years for surgeons with <10 THRs) differed only mini-
mally from our primary analyses (online supplementary 
table S9), indicating that our results were not biased by 
low- volume surgeons. In our second sensitivity analyses 
(‘consultant in- charge’ as the clustering variable) associa-
tions between source of funding and receipt of new stem/
cup were stronger, otherwise they differed only minimally 
differed from our primary analyses (online supplemen-
tary tables S10, S11). Our comparison of regression 
models without BMI as an exposure, with complete cases 
as defined previously (n=431 955) and complete cases 
defined without BMI (n=616 879) found only minor 
differences. This suggests that associations between the 
exposures and outcomes for the population missing BMI 
differ only slightly from the population with BMI.
DisCussiOn
Sixty- eight new cups and 72 new stems were first used in 
THRs in the NJR for OA between 2008 and 2017. Most 
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THRs used components introduced before 2008 but 8% 
used a new stem or cup. Uptake of some new implant 
components was very rapid. Conversely, uptake of a third 
of new components has been slow. Most surgeons used a 
maximum total of seven different cups or stems, of which 
one or two were new components. A small number of 
surgeons used a wide variety of different components, 
including new stems, cups and combinations.
Strengths of our study include the use of the NJR dataset, 
the largest arthroplasty register with comprehensive data 
capture (>95% in the period studied). This is the first to 
describe the variation in factors associated with uptake 
of new implant components by surgeons and receipt of 
new components by patients. Our study has several weak-
nesses. We classified a component as new based on the 
first record of a brand name in the NJR, but this does 
not exclude the possibility that a component was intro-
duced earlier to other markets outside the UK. Further-
more, new components may constitute procedures not 
uploaded to the NJR (missing primary THRs estimated 
<5%). Also, some of these components may be minor 
modifications or a rebadged/renamed version of an 
existing component and some may also cover successive 
versions of a component. The correct operating surgeon 
may not be assigned to every operation. The extent to 
which this applies is unknown but may result in inaccu-
rate estimates of surgeon- level associations, although 
our sensitivity analyses indicate that this is unlikely. The 
associations we have reported may be confounded by 
unmeasured factors (residual confounding) and in the 
absence of pre- existing literature on the uptake of new 
implants the findings from the regression models should 
be considered exploratory. We were missing BMI data for 
some people and elected not to use multiple imputation 
to account for these missing data, however our sensitivity 
analyses suggest that people with BMI data did not differ 
substantially from those without BMI across our other 
measures. Finally, we did not have data on hospital- level 
factors or regional variation in suppliers in our analyses 
which may be drivers of selection.15
Approximately 16 new implant components/year 
(stems and cups) were introduced in the NJR between 
2008 and 2017. Comparisons with Australia (34 implant 
components/year 2003–2008)16 and Finland (2–4 
components/year 1980–2013)17 suggest that this rate is 
not unusual, but that there is large variation internation-
ally. The rapid uptake of some new components indicates 
that phased introduction, as recommended in the IDEAL 
Framework and others,18 is unlikely to be happening. It is 
unclear whether 16 new implant components/year is of 
itself a good or bad thing. However, a healthcare system 
which supported a graduated introduction of new compo-
nents, where the use of new components is restricted to 
specialised centres,18 would provide a natural limit on 
the rate of introduction of new components until satis-
factory and robust evidence is generated to support their 
more widespread use. Conversely, a third of new implant 
components have not yet accrued more than ten uses. 
Postmarket surveillance of THRs, due to their longevity, 
performs a safety monitoring role which cannot easily be 
replaced by preapproval clinical data. Since the statistical 
methods are not applicable to components used in small 
numbers collaboration between international arthro-
plasty registries may allow more effective monitoring for 
low- volume components.
Over half of surgeons in our study used ≤5 different 
stems, cups or combinations, similar to a median of two 
different implant brands reported by surgeons in the USA 
in 1997.19 The volume of THRs performed by surgeons 
using new components was often low (median ≤3 THRs 
with new components vs median 22 THRs in total), but 
the proportion of their THRs using any new components 
varied from 1% (lower quartile) to 19% (upper quartile). 
Surgeons who use a wider range of prosthesis combina-
tions in THRs may have higher revision rates20 and early 
THRs performed after switching implants may have a 
higher revision risk (also known as ‘learning- curve’).21 
While this suggests that surgeons should rely on a narrow 
range of implant components and rarely switch, a phased 
introduction of new implant designs, as is done in Sweden, 
may mitigate the learning- curve effect.22 Since there are 
no contemporary comparisons of the range of implant 
components surgeons use and their relative volumes, it is 
unclear whether the between- surgeon variation we have 
reported may be associated with worse implant survival 
and warrants further research.
We found that newer components were being used 
in patients likely to be more active (ie, younger and/or 
male patients). There has been increasing evidence that 
uncemented implants, particularly stems, should not be 
used in older patients, but some uncertainty remains 
about their use in young patients (especially uncemented 
cups).23–25 Since the majority of new cups and stems are 
uncemented, the decision to use these implant compo-
nents in younger patients may increase the already high 
lifetime risk of revision surgery for these patients. Asso-
ciations between BMI or ASA grade and receipt or use 
of new components were inconsistent between stems and 
cups and did not provide clear support for the use of new 
implant components in patients likely to be more active 
(ie, lower BMI and ASA grades). It may be of interest to 
further investigate the implant component choices made 
for patients with higher BMI or ASA grades.
The most comparable previous work used NJR data to 
explore patient- level and hospital- level determinants that 
patients receive uncemented versus cemented implants.15 
Uncemented components were less likely to be used in 
women and older patients, and hospitals treating older 
patients were less likely to use them. Our results indicate 
that surgeons who treat a higher proportion of younger 
patients are more likely to use newer components. Our 
most marked finding, that surgeons who used a wide 
variety of stem- cup combinations (either established or 
new) were much more likely to try a new component, 
may be somewhat self- evident but suggests that there may 
be a subset of surgeons who change components more 
9Penfold CM, et al. BMJ Open 2019;9:e029572. doi:10.1136/bmjopen-2019-029572
Open access
quickly than their peers. Whether this behaviour, along-
side the previously discussed learning- curve, is related to 
outcomes of THRs is currently unclear.
Proposals for how new implant components should be 
introduced have been made previously, largely focused on 
phased introduction through high- volume centres and 
surgeons, and reliance on registries for long- term moni-
toring. It seems unlikely that 16 new THR implant compo-
nents/year, as we found in our study, could be sustained 
through such an approach. Alongside the potential 
benefits of phased introduction discussed elsewhere, this 
approach would probably reduce the number of implant 
components used only in very low numbers. Since these 
are not monitored in the same manner as higher volume 
components this would probably be a good thing for 
patients, providing implant components intended for use 
in specialist cases are not adversely affected.
Further research could build on the findings of this 
study in several ways. Extending our analysis of surgeon- 
level factors associated with uptake of new components to 
include factors associated with risk of revision after THR 
would be valuable to surgeons and patients. Specifically, 
the ‘learning curve’ associated with changing implants 
and the complex relationship between surgeon’s volume 
and outcomes. In addition, widening our study to cover 
hospital- level factors or regional variation in suppliers 
may highlight other drivers of selection.
COnClusiOns
A large number of new THR implant components have 
been introduced into use in the NJR since 2008. The 
majority of THRs performed since 2008 used compo-
nents which have been in use for a long time, but a large 
number of surgeons have tried new components, with 
wide variation in how many types and how often they 
have been used. The impact of this variation on patient 
outcomes is currently unclear. New rather than estab-
lished implant components are more likely to be used in 
patients who are younger and/or male, although whether 
this will reduce the high lifetime risk of revision for this 
population is unclear.
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